Novartis: legal dispute with United Therapeutics
(CercleFinance.com) - Sandoz has filed a lawsuit against United Therapeutics, alleging that the US drugmaker engaged in anti-competitive conduct as the Novartis biosimilar unit launched a generic version of Remodulin, a treatment of pulmonary arterial hypertension (PAH).
The case revolves around a system that is used by many patients to deliver the drug.
In a statement, United Therapeutics said it has made a significant investment to ensure the system would continue to be available to deliver Remodulin for a period of time.
The company says that Sandoz has failed to take similar steps to ensure availability of a system to deliver its own product.
Copyright (c) 2019 CercleFinance.com. All rights reserved.
The case revolves around a system that is used by many patients to deliver the drug.
In a statement, United Therapeutics said it has made a significant investment to ensure the system would continue to be available to deliver Remodulin for a period of time.
The company says that Sandoz has failed to take similar steps to ensure availability of a system to deliver its own product.
Copyright (c) 2019 CercleFinance.com. All rights reserved.